VSIR and cancer: Therefore, further mechanistic studies of PSGL-1 and VISTA in myeloid cells and T cells could uncover novel therapeutic targets for enhancing immune function (e.g., in cancer) or suppressing immune responses (e.g., in autoimmune diseases and transplant rejection) Fig. 2.